Table 2 Toxicity.
From: Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Entire cohort (n = 43) | t(11;14) | Non-t(11;14) | ||||
|---|---|---|---|---|---|---|
All grades | Grade 3 or higher | All grades | Grade 3 or higher | All grades | Grade 3 or higher | |
Gastrointestinal | ||||||
Diarrhea | 11 (26%) | 2 (5%) | 8 (26%) | 1 (3%) | 3 (27%) | 1 (9%) |
Nausea | 3 (7%) | 0 (0%) | 3 (10%) | 0 (0%) | 0 (0%) | 0 (0%) |
Abdominal pain | 1 (2%) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (9%) | 1 (9%) |
Unspecified | 2 (5%) | 0 (0%) | 2 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Central nervous system | ||||||
Fatigue | 8 (19%) | 0 (0%) | 4 (13%) | 0 (0%) | 3 (27%) | 0 (0%) |
Dizziness | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Cardiovascular | ||||||
Chest pain | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Dyspnea | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Musculoskeletal | ||||||
Shakiness | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Dermatological | ||||||
Rash | 2 (5%) | 0 (0%) | 1 (3%) | 0 (0%) | 1 (9%) | 0 (0%) |
Hematological | ||||||
Thrombocytopenia | 4 (9%) | 2 (5%) | 3 (10%) | 1 (3%) | 1 (9%) | 1 (9%) |
Leukopenia | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Neutropenia | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Infection | ||||||
Upper respiratory infection | 5 (12%) | 0 (0%) | 4 (13%) | 0 (0%) | 1 (9%) | 0 (0%) |
Sepsis | 2 (5%) | 2 (5%) | 1 (3%) | 1 (3%) | 1 (9%) | 1 (9%) |
Pneumonia | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Bronchitis | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Influenza | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Chest infection (unspecified) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Colitis | 1 (2%) | 1 (2%) | 1 (3%) | 1 (3%) | 0 (0%) | 0 (0%) |
Cellulitis | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Shingles | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Styes | 1 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
